Intec Pharma Ltd. (NASDAQ:NTEC) and Corcept Therapeutics Incorporated (NASDAQ:CORT) compete against each other in the Biotechnology sector. We will contrast them and contrast their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.
Earnings and Valuation
Table 1 shows gross revenue, earnings per share and valuation of the two companies.
Table 2 demonstrates the return on assets, return on equity and net margins of Intec Pharma Ltd. and Corcept Therapeutics Incorporated.
The table delivered features the ratings and recommendations for Intec Pharma Ltd. and Corcept Therapeutics Incorporated.
Competitively Corcept Therapeutics Incorporated has a consensus target price of $13, with potential upside of 5.43%.
Insider Institutional Ownership
Roughly 39.64% of Intec Pharma Ltd. shares are owned by institutional investors while 80.3% of Corcept Therapeutics Incorporated are owned by institutional investors. Insiders owned roughly 11.81% of Intec Pharma Ltd.’s shares.